Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers
Familial hypercholesterolemia is a common genetic disorder with a propensity towards early onset of atherosclerotic cardiovascular disease (CVD). The main goal of therapy is to reduce the LDL cholesterol and the current treatment generally consists of statin, ezetimibe and PCSK9 inhibitors. Unfortun...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142551/ https://www.ncbi.nlm.nih.gov/pubmed/37111513 http://dx.doi.org/10.3390/pathogens12040627 |
_version_ | 1785033639978860544 |
---|---|
author | Piccioni, Andrea Niccolai, Elena Rozzi, Gloria Spaziani, Giacomo Zanza, Christian Candelli, Marcello Covino, Marcello Gasbarrini, Antonio Franceschi, Francesco Amedei, Amedeo |
author_facet | Piccioni, Andrea Niccolai, Elena Rozzi, Gloria Spaziani, Giacomo Zanza, Christian Candelli, Marcello Covino, Marcello Gasbarrini, Antonio Franceschi, Francesco Amedei, Amedeo |
author_sort | Piccioni, Andrea |
collection | PubMed |
description | Familial hypercholesterolemia is a common genetic disorder with a propensity towards early onset of atherosclerotic cardiovascular disease (CVD). The main goal of therapy is to reduce the LDL cholesterol and the current treatment generally consists of statin, ezetimibe and PCSK9 inhibitors. Unfortunately, lowering LDL cholesterol may be difficult for many reasons such as the variation of response to statin therapy among the population or the high cost of some therapies (i.e., PCSK9 inhibitors). In addition to conventional therapy, additional strategies may be used. The gut microbiota has been recently considered to play a part in chronic systemic inflammation and hence in CVD. Several studies, though they are still preliminary, consider dysbiosis a risk factor for various CVDs through several mechanisms. In this review, we provide an update of the current literature about the intricate relation between the gut microbiota and the familial hypercholesterolemia. |
format | Online Article Text |
id | pubmed-10142551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101425512023-04-29 Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers Piccioni, Andrea Niccolai, Elena Rozzi, Gloria Spaziani, Giacomo Zanza, Christian Candelli, Marcello Covino, Marcello Gasbarrini, Antonio Franceschi, Francesco Amedei, Amedeo Pathogens Review Familial hypercholesterolemia is a common genetic disorder with a propensity towards early onset of atherosclerotic cardiovascular disease (CVD). The main goal of therapy is to reduce the LDL cholesterol and the current treatment generally consists of statin, ezetimibe and PCSK9 inhibitors. Unfortunately, lowering LDL cholesterol may be difficult for many reasons such as the variation of response to statin therapy among the population or the high cost of some therapies (i.e., PCSK9 inhibitors). In addition to conventional therapy, additional strategies may be used. The gut microbiota has been recently considered to play a part in chronic systemic inflammation and hence in CVD. Several studies, though they are still preliminary, consider dysbiosis a risk factor for various CVDs through several mechanisms. In this review, we provide an update of the current literature about the intricate relation between the gut microbiota and the familial hypercholesterolemia. MDPI 2023-04-21 /pmc/articles/PMC10142551/ /pubmed/37111513 http://dx.doi.org/10.3390/pathogens12040627 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Piccioni, Andrea Niccolai, Elena Rozzi, Gloria Spaziani, Giacomo Zanza, Christian Candelli, Marcello Covino, Marcello Gasbarrini, Antonio Franceschi, Francesco Amedei, Amedeo Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers |
title | Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers |
title_full | Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers |
title_fullStr | Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers |
title_full_unstemmed | Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers |
title_short | Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers |
title_sort | familial hypercholesterolemia and acute coronary syndromes: the microbiota–immunity axis in the new diagnostic and prognostic frontiers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142551/ https://www.ncbi.nlm.nih.gov/pubmed/37111513 http://dx.doi.org/10.3390/pathogens12040627 |
work_keys_str_mv | AT piccioniandrea familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT niccolaielena familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT rozzigloria familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT spazianigiacomo familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT zanzachristian familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT candellimarcello familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT covinomarcello familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT gasbarriniantonio familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT franceschifrancesco familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers AT amedeiamedeo familialhypercholesterolemiaandacutecoronarysyndromesthemicrobiotaimmunityaxisinthenewdiagnosticandprognosticfrontiers |